TY - JOUR
T1 - Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine
AU - Podda, Audino
AU - Carapella De Luca, Erminia
AU - Contu, Bruno
AU - Furlan, Riccardo
AU - Maida, Alessandro
AU - Moiraghi, Angela
AU - Stramare, Duilio
AU - Titone, Lucina
AU - Uxa, Fabio
AU - Di Pisa, Francesco
AU - Peppoloni, Samuele
AU - Nencioni, Luciano
AU - Rappuoli, Rino
N1 - Funding Information:
Supported in part (the Rome center) by a grant from the Italian Ministry of Health (legge 12.12.69 No. 1020).
PY - 1994/6
Y1 - 1994/6
N2 - The safety and immunogenicity of an acellular pertussis vaccine containing the genetically detoxified pertussis toxin PT-9K/129C, filamentous hemagglutinin, and pertactin, together with diphtheria and tetanus toxoids, were compared with those of a whole-cell pertussis component-diphtheria-tetanus vaccine. Four hundred eighty infants were enrolled into this prospective, multicenter, double-blind study. Each infant was randomly given three doses of one of the two vaccines at 2, 4, and 6 months of age. Both local and systemic adverse reactions, reported within 48 hours and 7 days of each injection, were less frequent after the acellular vaccine than after the whole-cell vaccine. The enzyme-linked immunosorbent assay titers to pertussis toxin, filamentous hemagglutinin, and pertactin, as well as the pertussis toxin-neutralizing titer measured by the Chinese hamster ovary cell assay, were significantly higher after the acellular vaccine was given. Both vaccines induced adequate levels of anti-diphtheria and anti-tetanus antibodies. We conclude that the recombinant acellular pertussis vaccine produces fewer reactions than the whole-cell vaccine and provides a high antibody response against the antigens of Bordetella pertussis involved in bacterial adhesion and systemic toxic effects.
AB - The safety and immunogenicity of an acellular pertussis vaccine containing the genetically detoxified pertussis toxin PT-9K/129C, filamentous hemagglutinin, and pertactin, together with diphtheria and tetanus toxoids, were compared with those of a whole-cell pertussis component-diphtheria-tetanus vaccine. Four hundred eighty infants were enrolled into this prospective, multicenter, double-blind study. Each infant was randomly given three doses of one of the two vaccines at 2, 4, and 6 months of age. Both local and systemic adverse reactions, reported within 48 hours and 7 days of each injection, were less frequent after the acellular vaccine than after the whole-cell vaccine. The enzyme-linked immunosorbent assay titers to pertussis toxin, filamentous hemagglutinin, and pertactin, as well as the pertussis toxin-neutralizing titer measured by the Chinese hamster ovary cell assay, were significantly higher after the acellular vaccine was given. Both vaccines induced adequate levels of anti-diphtheria and anti-tetanus antibodies. We conclude that the recombinant acellular pertussis vaccine produces fewer reactions than the whole-cell vaccine and provides a high antibody response against the antigens of Bordetella pertussis involved in bacterial adhesion and systemic toxic effects.
UR - http://www.scopus.com/inward/record.url?scp=0028232732&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(05)83181-6
DO - 10.1016/S0022-3476(05)83181-6
M3 - Article
SN - 0022-3476
VL - 124
SP - 921
EP - 926
JO - Journal of Pediatrics
JF - Journal of Pediatrics
IS - 6
ER -